Back to Search
Start Over
Cancer and Immune Response: Old and New Evidence for Future Challenges.
- Source :
- Oncologist; Dec2008, Vol. 13 Issue 12, p1246-1254, 9p, 2 Diagrams, 2 Charts
- Publication Year :
- 2008
-
Abstract
- Cancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has been recognized as a good prognostic factor in several types of tumors. Some chemotherapy agents, such as anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell availability in the tumor vicinity, and thus improve both antigen presentation and T-cell activation and proliferation. In addition, cytotoxic T lymphocyte antigen 4 -- blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation. Strategies to stimulate the dormant immune system against tumors are varied and warrant further investigation of their applications to cancer therapy in the future. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER
IMMUNE response
IMMUNE system
T cells
ANTHRACYCLINES
DRUG therapy
TUMORS
Subjects
Details
- Language :
- English
- ISSN :
- 10837159
- Volume :
- 13
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Oncologist
- Publication Type :
- Academic Journal
- Accession number :
- 36351230
- Full Text :
- https://doi.org/10.1634/theoncologist.2008-0166